Author's response to reviews

Title: Preclinical and clinical phase I studies of a new recombinant Filgrastim (BK0023) in comparison with Neupogen(R).

Authors:

Davide Crobu (davide.crobu@multimedica.it)
Gaia Spinetti (gaia.spinetti@multimedica.it)
Rodolfo Schrepfer (rodolfo.schrepfer@multimedica.it)
Giancarlo Tonon (giancarlo.tonon@multimedica.it)
Gloria Saccani Jotti (gloria.saccani@unipr.it)
Pierluigi Onali (onali@unica.it)
Simona Dedoni (dedoni@unica.it)
Gaetano Orsini (orsini.g@libero.it)
Andrea Di Stefano (andrea.distefano@croalliance.com)

Version: 2 Date: 12 September 2013

Author's response to reviews: see over
To the Editors of the
BMC Pharmacology and Toxicology

Pula, September 12th, 2013

Dear Sirs,
attached please find the manuscript by Crobu et al., entitled “Preclinical and clinical phase I studies of a new recombinant Filgrastim (BK0023) in comparison with Neupogen®” with the following amendments as requested by the Editor in date July 26th 2013:

1. Number of clinical trial registration (TNR), last line of the manuscript abstract.
2. Statement of informed consent signature from participants to the study (Materials and methods, page 16)

We thank you very much for the consideration.

Looking forward to hearing from you.

Best regards.

Dr. Davide Crobu
(Corresponding author)

Address: Bioker srl, c/o Sardinia Scientific and Technological Park, Building 3, 09010 Pula (Cagliari), Italy
Tel. +39 070 9243 3183; fax +39 070 9243 3181
Email: davide.crobu@multimedica.it